Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 23

1.

Identification of miRNA-7 as a regulator of brain-derived neurotrophic factor/α-synuclein axis in atrazine-induced Parkinson's disease by peripheral blood and brain microRNA profiling.

Li B, Jiang Y, Xu Y, Li Y, Li B.

Chemosphere. 2019 May 23;233:542-548. doi: 10.1016/j.chemosphere.2019.05.064. [Epub ahead of print]

PMID:
31185338
2.

Benefits of curcumin in brain disorders.

Bhat A, Mahalakshmi AM, Ray B, Tuladhar S, Hediyal TA, Manthiannem E, Padamati J, Chandra R, Chidambaram SB, Sakharkar MK.

Biofactors. 2019 Jun 11. doi: 10.1002/biof.1533. [Epub ahead of print] Review.

PMID:
31185140
3.

The interaction of several herbal extracts with α-synuclein: Fibril formation and surface plasmon resonance analysis.

Honarmand S, Dabirmanesh B, Amanlou M, Khajeh K.

PLoS One. 2019 Jun 11;14(6):e0217801. doi: 10.1371/journal.pone.0217801. eCollection 2019.

4.

[Prion Properties of Alpha-Synuclein].

Schwarzman AL, Senkevich KA, Emelyanov AK, Pchelina SN.

Mol Biol (Mosk). 2019 May-Jun;53(3):380-387. doi: 10.1134/S0026898419030182. Russian.

PMID:
31184602
5.

A Hallmark Clinical Study of Cord Blood Therapy in Adults with Ischemic Stroke.

Sanberg PR, Ehrhart J.

Cell Transplant. 2019 Jun 11:963689719854354. doi: 10.1177/0963689719854354. [Epub ahead of print]

PMID:
31184206
6.

Immunoreactivity of myelin-associated oligodendrocytic basic protein in Lewy bodies.

Kon T, Tanji K, Mori F, Kimura A, Kakita A, Wakabayashi K.

Neuropathology. 2019 Jun 10. doi: 10.1111/neup.12564. [Epub ahead of print]

PMID:
31183926
7.

Nasal Cavity Administration of Melanin-Concentrating Hormone Improves Memory Impairment in Memory-Impaired and Alzheimer's Disease Mouse Models.

Oh ST, Liu QF, Jeong HJ, Lee S, Samidurai M, Jo J, Pak SC, Park HJ, Kim J, Jeon S.

Mol Neurobiol. 2019 Jun 10. doi: 10.1007/s12035-019-01662-1. [Epub ahead of print]

PMID:
31183806
8.

Skin Fibroblasts as the Object for Clinical Diagnosis of Parkinson's Disease in Persons of Different Ages.

Zuev VA, Dyatlova AS, Lin'kova NS, Kvetnoi IM, Belushkina NN, Pal'tsev VA.

Bull Exp Biol Med. 2019 Jun 10. doi: 10.1007/s10517-019-04485-1. [Epub ahead of print]

PMID:
31183656
9.

A metabolomic signature of treated and drug-naïve patients with Parkinson's disease: a pilot study.

Troisi J, Landolfi A, Vitale C, Longo K, Cozzolino A, Squillante M, Savanelli MC, Barone P, Amboni M.

Metabolomics. 2019 Jun 10;15(6):90. doi: 10.1007/s11306-019-1554-x.

PMID:
31183578
10.

Fourier-Based Footfall Placement Variability in Parkinson's Disease.

Shin S, Lim BO, Socie MJ, Sosonff JJ, Lee KK.

Biomed Res Int. 2019 Apr 30;2019:2689609. doi: 10.1155/2019/2689609. eCollection 2019.

11.

Patient Satisfaction in Surgery for Parkinson's Disease: A Systematic Review of the Literature.

Elsayed GA, Menendez JY, Tabibian BE, Chagoya G, Omar NB, Zeiger E, Walters BC, Walker H, Guthrie BL.

Cureus. 2019 Mar 25;11(3):e4316. doi: 10.7759/cureus.4316. Review.

12.

Telepsychiatry for patients with movement disorders: a feasibility and patient satisfaction study.

Seritan AL, Heiry M, Iosif AM, Dodge M, Ostrem JL.

J Clin Mov Disord. 2019 Jun 6;6:1. doi: 10.1186/s40734-019-0077-y. eCollection 2019.

13.

Triptolide Inhibits Preformed Fibril-Induced Microglial Activation by Targeting the MicroRNA155-5p/SHIP1 Pathway.

Feng Y, Zheng C, Zhang Y, Xing C, Cai W, Li R, Chen J, Duan Y.

Oxid Med Cell Longev. 2019 Apr 28;2019:6527638. doi: 10.1155/2019/6527638. eCollection 2019.

14.

GM1 Ganglioside Modifies α-Synuclein Toxicity and is Neuroprotective in a Rat α-Synuclein Model of Parkinson's Disease.

Schneider JS, Aras R, Williams CK, Koprich JB, Brotchie JM, Singh V.

Sci Rep. 2019 Jun 10;9(1):8362. doi: 10.1038/s41598-019-42847-x.

15.

Persistent Toxoplasma Infection of the Brain Induced Neurodegeneration associated with Activation of Complement and Microglia.

Li Y, Severance EG, Viscidi RP, Yolken RH, Xiao J.

Infect Immun. 2019 Jun 10. pii: IAI.00139-19. doi: 10.1128/IAI.00139-19. [Epub ahead of print]

PMID:
31182619
16.

Quality of life predicts outcome of deep brain stimulation in early Parkinson disease.

[No authors listed]

Neurology. 2019 Jun 11;92(24):1166. doi: 10.1212/WNL.0000000000007420. No abstract available.

PMID:
31182520
17.

Parkinson's disease in traditional Chinese medicine.

Li S, Le W.

Lancet Neurol. 2019 Jun 7. pii: S1474-4422(19)30224-8. doi: 10.1016/S1474-4422(19)30224-8. [Epub ahead of print] No abstract available.

PMID:
31182383
18.

Substantia nigra locations of iron-content, free-water and mean diffusivity abnormalities in moderate stage Parkinson's disease.

Arribarat G, Pasternak O, De Barros A, Galitzky M, Rascol O, Péran P.

Parkinsonism Relat Disord. 2019 May 22. pii: S1353-8020(19)30254-8. doi: 10.1016/j.parkreldis.2019.05.033. [Epub ahead of print]

PMID:
31182373
19.

Gait stride-to-stride variability and foot clearance pattern analysis in Idiopathic Parkinson's Disease and Vascular Parkinsonism.

Ferreira F, Gago MF, Bicho E, Carvalho C, Mollaei N, Rodrigues L, Sousa N, Rodrigues PP, Ferreira C, Gama J.

J Biomech. 2019 May 30. pii: S0021-9290(19)30383-5. doi: 10.1016/j.jbiomech.2019.05.039. [Epub ahead of print]

PMID:
31182234
20.

Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus.

Black KJ, Nasrallah H, Isaacson S, Stacy M, Pahwa R, Adler CH, Alva G, Cooney JW, Kremens D, Menza MA, Meyer JM, Patkar AA, Simuni T, Morrissette DA, Stahl SM.

CNS Spectr. 2019 Jun 11:1-2. doi: 10.1017/S1092852919000932. [Epub ahead of print] No abstract available.

PMID:
31182180

Supplemental Content

Loading ...
Support Center